Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 03 2019 - 7:00AM
Business Wire
Sesen Bio (Nasdaq: SESN), a late-stage clinical company
developing targeted fusion protein therapeutics for the treatment
of patients with cancer, today announced it will be featured as a
presenting company at the H.C. Wainwright 21st Annual Global
Investment Conference on Tuesday, September 10, 2019 in New York,
NY.
Event: H.C. Wainwright 21st Annual Global Investment Conference
Date: September 10, 2019 Time: 3:25-3:50 PM EDT Location: Holmes I
(4th Floor) room, Lotte New York Palace Hotel, New York, NY
A live webcast of the Company’s presentation will be accessible
from the Investors & Media section of Sesen Bio’s website,
www.sesenbio.com. An archived replay of the webcast will be
available on the Company's website for 90 days after the
conference.
About Sesen Bio Sesen Bio, Inc. is a late-stage clinical
company advancing targeted fusion protein therapeutics for the
treatment of patients with cancer. The Company’s lead program,
Vicinium®, also known as VB4-845, is currently in a Phase 3
registration trial, the VISTA trial, for the treatment of
high-risk, BCG-unresponsive non-muscle invasive bladder cancer
(NMIBC). Vicinium is a locally-administered targeted fusion protein
composed of an anti-EPCAM antibody fragment tethered to a truncated
form of Pseudomonas Exotoxin A for the treatment of high-risk
NMIBC. For more information, please visit the Company’s website at
www.sesenbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190903005155/en/
Chad Myskiw, Ph.D. Sr. Dir., Strategic Planning
ir@sesenbio.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Sep 2023 to Sep 2024